Skip to main content
SunBio, Inc. logo

SunBio, Inc. — Investor Relations & Filings

Ticker · 067370 ISIN · KR7067370007 KO Manufacturing
Open in API
Filings indexed 213 across all filing types
Latest filing 2022-09-01 Regulatory Filings
Country KR South Korea
Listing KO 067370

About SunBio, Inc.

http://www.sunbio.com/

SunBio, Inc. is a biotechnology company that develops biosimilars, biopharmaceuticals, and medical devices. The company's core activities are based on its proprietary PEGylation technology, a process that modifies molecules to enhance their therapeutic properties. SunBio's product portfolio includes PEG reagents for research and drug delivery, as well as biopharmaceutical candidates. Key development projects include MucoPEG™, a muco-adhesive hydrogel, and SBX, an artificial blood substitute. The company positions itself as a specialist in PEGylation, creating advanced therapeutic products for a global market.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권) (2022.09)
Regulatory Filings Classification · 1% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement for Equity Securities) filed with the Financial Supervisory Service (FSS) in South Korea. It details a registration statement for a public offering of shares, including information on investment risks, legal compliance, and management. This is a formal regulatory filing required for public offerings and does not fit into the other specific categories like earnings releases or annual reports. Therefore, it is classified as a Regulatory Filing (RNS).
2022-09-01 Korean
[기재정정]증권신고서(지분증권) (2022.09)
Share Issue/Capital Change Classification · 1% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement for Equity Securities) filed by SunBio Co., Ltd. It explicitly mentions '정정신고' (Amendment Filing) and provides a history of previous filings. This is a formal regulatory document required for public offerings of securities, which falls under the category of Regulatory Filings (RNS) as it is a specific type of regulatory disclosure that does not fit into the other specialized categories like 10-K or Earnings Release.
2022-08-31 Korean
[기재정정]증권신고서(지분증권) (2022.09)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Amendment to Securities Registration Statement for Equity Securities) filed by SunBio. It details specific amendments to a previously filed registration statement, including changes to the offering schedule, subscription dates, and various risk factors. In the context of financial filings, a Securities Registration Statement (and its amendments) is a primary regulatory document for public offerings. Among the provided categories, 'Regulatory Filings' (RNS) serves as the appropriate fallback for this type of formal regulatory submission that does not fit into specific categories like 10-K, ER, or others.
2022-08-30 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Capital Increase Decision' (유상증자결정) and specifically a 'Correction Report' (정정신고). It details the subscription dates, payment dates, and procedures for a capital increase (IPO/Rights Offering). This falls under the category of announcements regarding share issues and capital changes.
2022-08-30 Korean
증권신고서(지분증권) (2022.09)
Share Issue/Capital Change Classification · 1% confidence The document is a '증권신고서' (Securities Registration Statement) filed by SunBio Co., Ltd. with the Financial Services Commission (FSC) in South Korea. It contains detailed information regarding a public offering of shares, including investment risks, business overview, and financial disclosures, which is characteristic of a formal regulatory filing for an IPO or capital raise. It is not a simple announcement (RPA) but the primary regulatory document itself.
2022-08-19 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the issuance of new shares, the purpose of funds, subscription dates, and underwriting details by Hana Securities. This is a formal regulatory filing concerning capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2022-08-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.